

Enfermedad del hígado graso no alcohólico

Referencias

1. Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med* 2002;346:1221-31.
2. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. *J Clin Endocrinol Metab* 2008;93: Suppl 1:S74-S80.
3. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2008;28:27-38.
4. de Alwis NMW, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. *J Hepatol* 2008;48:Suppl 1:S104- S112.
5. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in nonalcoholic fatty liver disease: causal effect or epiphenomenon? *Diabetologia* 2008;51:1947-53.
6. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. *Hepatology* 2005;42:473-80.
7. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. *Diabetes Care* 2004;27:2498-500.
8. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. *Arterioscler Thromb Vasc Biol* 2005;25:1045-50.
9. Volzke H, Robinson DM, Kleine V, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. *World J Gastroenterol* 2005;11:1848-53.
10. Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. *Diabetes Care* 2006;29:1325-30.
11. Fracanzani AL, Burdick L, Raselli S, et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. *Am J Med* 2008;121:72-8.
12. Kim HC, Kim D, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. *Atherosclerosis* 2009;204:521-5.
13. McKimmie RL, Daniel KR, Carr JJ, et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. *Am J Gastroenterol* 2008;103:3029- 35.
14. Petit JM, Guiu B, Terriat B, et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. *J Clin Endocrinol Metab* 2009;94:4103-6.
15. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. *J Hepatol* 2008;49:600-7.
16. Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease:echocardiographic and tissue Doppler imaging assessment. *J Clin Gastroenterol* 2006;40:949-55.
17. Perseghin G, Lattuada G, De Cobelli F, et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. *Hepatology* 2008;47:51-8.

18. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care* 2007;30:1212-8.
19. Targher G, Bertolini L, Padovani R, et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. *J Hepatol* 2010;53:713-8.
20. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. *World J Gastroenterol* 2005;11:4838-42.
21. Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: an alarm for the heart? *Liver Int* 2007;27:891-4.
22. Lautamaki R, Borra R, Iozzo P, et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. *Am J Physiol Endocrinol Metab* 2006;291:E282-E290.
23. Schwimmer JB, Deutsch R, Behling C, Lavine JE. Fatty liver as a determinant of atherosclerosis. *Hepatology* 2005;42:Suppl:610A. abstract.
24. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu LC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999;116:1413-9.
25. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long-term prognosis of fatty liver: risk of chronic liver disease and death. *Gut* 2004;53:750-5.
26. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005;129:113-21.
27. Rafiq N, Bai C, Fang Y, et al. Longterm follow-up of patients with non-alcoholic fatty liver. *Clin Gastroenterol Hepatol* 2009;7:234-8.
28. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006;44:865-73.
29. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. *Hepatology* 2010;51:595-602.
30. Ruttman E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. *Circulation* 2005;112:2130-7.
31. Lee DH, Silventoinen K, Hu G, et al. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. *Eur Heart J* 2006;27:2170-6.
32. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10- year follow-up of the Hoorn Study. *Atherosclerosis* 2007;191:391-6.
33. Lee DS, Evans JC, Robins SJ, et al. Gamma-glutamyltransferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. *Arterioscler Thromb Vasc Biol* 2007;27:127-33.
34. Wannamethee SG, Lennon L, Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. *Atherosclerosis* 2008;201:168-75.
35. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and meta-analysis. *Arterioscler Thromb Vasc Biol* 2007; 27:2729-35. [Erratum, *Arterioscler Thromb Vasc Biol* 2008;28(2):e14.]

36. Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. *Am J Gastroenterol* 2008;103:2263-71.
37. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. *Gastroenterology* 2008;135:1935-44.
38. Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gammaglutamyltransferase and mortality in the United States population. *Gastroenterology* 2009;136:477-85.
39. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. *Atherosclerosis* 2009;205:533-7.
40. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. *World J Gastroenterol* 2007;13:1579-84.
41. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. *Diabetes* 2005; 54:3541-6.
42. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. *Diabetes Care* 2007; 30:2119-21.
43. Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. *Hepatology* 2009;50:1403-11.
44. Groll DL, To T, Bombardier C, Wright JG. The development of a comorbidity index with physical function as the outcome. *J Clin Epidemiol* 2005;58:595-602.
45. Badman MK, Flier JS. The adipocyte as an active participant in the energy balance and metabolism. *Gastroenterology* 2007;132:2103-15.
46. Day CP. From fat to inflammation. *Gastroenterology* 2006;130:207-10.
47. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. *Gastroenterology* 2007;132:2169-80.
48. Stefan N, Kantartzis K, Haring HU. Causes and metabolic consequences of fatty liver. *Endocr Rev* 2008;29:939-60.
49. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. *Trends Endocrinol Metab* 2008;19:371-9.
50. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. *N Engl J Med* 2002;347:185-92.
51. Sabio G, Das M, Mora A, et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. *Science* 2008;322:1539-43.
52. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. *Physiol Rev* 2007;87:507-20.
53. Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proc Natl Acad Sci U S A* 2007;104:12587-94.
54. Bonora E. The metabolic syndrome and cardiovascular disease. *Ann Med* 2006;38:64-80.
55. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. *Semin Thromb Hemost* 2009;35:277-87.
56. Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-reactive protein is an independent clinical feature of non-alcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. *J Gastroenterol* 2007;42:573-82.

57. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. *Am J Gastroenterol* 2008;103:1372-9.
58. Thuy S, Ladurner R, Volynets V, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. *J Nutr* 2008;138:1452-5.
59. Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. *Obesity (Silver Spring)* 2008;16:1394-9.
60. Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with nonalcoholic steatohepatitis and chronic hepatitis B and C. *J Hepatol* 2007;46:1126-32.
61. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. *Hepatology* 2003;37:909-16.
62. Matikainen N, Manttari S, Westerbacka J, et al. Postprandial lipemia associates with liver fat content. *J Clin Endocrinol Metab* 2007;92:3052-9.
63. Harrison SA, Day CP. Benefits of lifestyle modifications in NAFLD. *Gut* 2007;56:1760-9.
64. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. *Diabetes* 2005;54:603-8.
65. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. *Diabetes* 2003;52:1364-70.
66. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006;355:2297-307.
67. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med* 2007;356:2457-71.[Erratum, *N Engl J Med* 2007;357:100.]
68. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA* 2007;298:1180-8.
69. Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. *Hepatology* 2006;44:466-71.
70. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010;362:1675-85.